Company Progen Co., Ltd.

Equities

A296160

KR7296160005

Biotechnology & Medical Research

End-of-day quote Korea S.E. 03:30:00 28/06/2024 am IST 5-day change 1st Jan Change
5,940 KRW +0.17% Intraday chart for Progen Co., Ltd. +0.68% -16.92%

Business Summary

Progen Co Ltd is a Korea-based company principally engaged in the researching and developing new drugs. The Company produces metabolic disease treatment drugs, immune disease treatment drugs, immune anticancer drugs, and others. The Company was established in 1998.

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 1,228,071 0 0 78.76 %
Stock B 0 4,190,003 0 0
Stock C 0 263,000 0 0
Stock D 1 11,557,263 9,102,215 ( 78.76 %) 3,000 ( 0.0260 %)
Stock E 0 1,837,000 0 0

Shareholders

NameEquities%Valuation
4,246,278 36.75 % 19 M ₩
2,095,002 18.13 % 9 M ₩
1,783,306 15.43 % 8 M ₩
InterVest Co., Ltd.
14.45 %
1,670,000 14.45 % 7 M ₩
Kclavis Investment Co. Ltd.
4.327 %
500,000 4.327 % 2 M ₩
299,715 2.594 % 1 M ₩
255,286 2.209 % 1 M ₩
250,000 2.164 % 1 M ₩
202,000 1.748 % 889 964 ₩
Sang In Yang
1.748 %
202,000 1.748 % 889 964 ₩

Company contact information

Progen Co., Ltd.

Bio Innovation Park 172 Magokjungang-ro

07789, Seoul

+

http://www.progen.co.kr
address Progen Co., Ltd.(A296160)
  1. Stock Market
  2. Equities
  3. A296160 Stock
  4. Company Progen Co., Ltd.